Related Experiment Videos
[Development of immunizing agents against dengue].
1Instituto Nacional de Salud Pública, Cuernavaca, Morelos, México. alantu@insp3.insp.mx
Summary
Developing effective dengue vaccines is crucial due to the global threat of all four dengue virus serotypes. Research focuses on tetravalent vaccines, with candidate vaccines showing promise in safety and immunogenicity.
Area of Science:
- * Virology and Immunology
- * Vaccine Development
- * Public Health
Context:
- * Dengue viruses (DENV) pose a significant global health challenge, transmitted primarily by Aedes mosquitoes.
- * Dengue morbidity and mortality are influenced by host factors (genetics, immunity, lifestyle) and viral characteristics (serotype, pathogenicity, distribution).
- * Natural infection confers type-specific immunity, necessitating a tetravalent vaccine approach due to potential sequential infections.
Purpose:
- * To review the progress and challenges in developing dengue vaccines.
- * To highlight the need for a tetravalent vaccine effective against all four DENV serotypes.
- * To discuss various vaccine technologies and candidate approaches.
Summary:
- * Decades of research have pursued dengue vaccines, with recent efforts focusing on attenuated viruses and recombinant technologies, particularly targeting the E glycoprotein.
- * Candidate tetravalent vaccines have demonstrated immunogenicity and safety in trials, though further studies on effectiveness and long-term safety are required.
- * Various expression vectors (e.g., E. coli, baculovirus) are employed in vaccine production, but human efficacy remains a challenge.
Impact:
- * An effective dengue vaccine would significantly contribute to disease prevention and control worldwide.
- * Immunization programs, especially for children in endemic areas, could reduce the burden of dengue.
- * Successful dengue vaccination offers a positive cost-benefit ratio for public health interventions.